RIGL
Rigel Pharmaceuticals Inc
48.10$
-1.4%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| -21.2% | -57.2% | 236.1% | 303.6% | 445.2% | 1,254.0% | 7.0% | 224.4% | 720.5% | – | 187.1% | 70.7% | 1,877.1% | 4,408.6% | 1,053.5% | 820.6% | 217.4% | 311.3% | 1,031.9% | 0.6% | 1.5% | 0.8% | 0.7% | 1.5% | 6.1% | 10.4% | 6.7% | |
| 121.2% | 157.2% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | 100.0% | 100.0% | 100.0% | -953.5% | -720.6% | -117.4% | -211.3% | -931.9% | 99.4% | 98.5% | 99.2% | 99.3% | 98.5% | 93.9% | 89.6% | 93.3% | |
| 190.5% | 242.4% | 211.2% | 274.6% | 392.2% | 1,025.2% | 314.9% | 170.2% | 558.4% | – | 12,099.1% | 51.5% | 1,460.0% | 3,501.2% | 1,053.5% | 820.6% | 217.4% | 311.3% | 1,031.9% | 105.4% | 89.2% | 55.3% | 43.7% | 50.1% | 21.0% | 13.0% | 11.3% | |
| – | 50.6% | 52.0% | 59.9% | 77.1% | 276.3% | 75.1% | 58.4% | 172.7% | – | 2,787.1% | 20.2% | 458.3% | 1,015.5% | 274.3% | 385.5% | 61.6% | 102.6% | 843.7% | 157.3% | 125.8% | 70.5% | 61.6% | 93.5% | 95.0% | 63.1% | 39.4% | |
| 255.7% | 350.1% | 263.1% | 334.5% | 469.3% | 1,301.5% | 383.0% | 228.6% | 731.2% | – | 14,886.1% | 71.7% | 1,918.3% | 4,516.8% | 1,351.3% | 1,206.0% | 279.1% | 442.2% | 1,875.6% | 262.7% | 215.0% | 125.8% | 107.6% | 144.7% | 111.4% | 76.1% | 50.7% | |
| -134.5% | -193.0% | -163.1% | -234.5% | -369.3% | -1,201.5% | -290.0% | -128.6% | -631.2% | – | -14,938.3% | 28.3% | -1,818.3% | -4,416.8% | -1,251.3% | -1,106.0% | -179.1% | -342.2% | -1,775.6% | -163.3% | -116.5% | -26.7% | -8.4% | -46.2% | -17.5% | 13.5% | 42.6% | |
| 0.0% | 7.1% | 5.2% | 5.5% | 5.2% | 6.8% | 1.7% | 0.9% | 1.8% | – | 27.1% | 0.1% | 0.5% | 0.8% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.6% | 1.2% | 3.3% | 3.1% | 5.9% | 4.4% | 2.5% | |
| – | -191.9% | -155.6% | -234.5% | -372.7% | -1,188.6% | -273.8% | -112.4% | -589.5% | – | -14,885.3% | 30.3% | -1,810.0% | -4,392.9% | -1,245.1% | -1,101.9% | -178.1% | -339.6% | -1,739.3% | -158.3% | -112.8% | -27.4% | -11.6% | -48.7% | -21.5% | 10.2% | 41.4% | |
| 3.2% | – | – | – | 3.3% | -12.9% | – | – | – | – | -12.4% | 0.1% | 8.8% | -108.1% | 0.0% | -32.7% | -5.9% | 21.1% | -46.6% | 4.9% | -0.6% | 0.6% | 0.4% | 2.5% | 1.9% | 0.5% | -83.3% | |
| -137.6% | -191.9% | -155.6% | -234.5% | -372.7% | -1,188.6% | -273.8% | -112.4% | -589.5% | – | -14,872.9% | 30.3% | -1,810.0% | -4,392.9% | -1,245.1% | -1,101.9% | -178.1% | -339.6% | -1,739.3% | -158.3% | -112.2% | -27.4% | -12.0% | -48.7% | -21.5% | 9.8% | 124.7% | |
| -113.2% | -135.8% | -118.9% | -197.6% | -340.6% | -1,151.4% | -282.8% | -124.4% | -631.2% | – | -14,671.2% | 31.4% | -1,768.3% | -4,308.6% | -1,191.6% | -1,077.5% | -174.1% | -309.2% | -1,729.0% | -162.0% | -111.1% | -25.5% | -7.6% | -44.8% | -14.5% | 15.9% | 44.7% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.